Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) Sees Large Drop in Short Interest

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) saw a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 19,300 shares, a decrease of 93.8% from the January 15th total of 311,700 shares. Based on an average daily trading volume, of 1,990,000 shares, the days-to-cover ratio is presently 0.0 days. Approximately 1.3% of the company’s stock are sold short.

Salarius Pharmaceuticals Stock Down 5.5 %

Shares of NASDAQ SLRX traded down $0.10 during trading hours on Wednesday, hitting $1.71. The company had a trading volume of 60,845 shares, compared to its average volume of 4,547,321. The stock has a market capitalization of $2.70 million, a P/E ratio of -0.21 and a beta of 0.84. Salarius Pharmaceuticals has a 1-year low of $1.22 and a 1-year high of $7.20. The firm’s 50 day moving average is $1.93 and its 200-day moving average is $1.78.

Salarius Pharmaceuticals Company Profile

Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.